Derek Archila
Stock Analyst at Wells Fargo
(2.08)
# 2,746
Out of 4,826 analysts
178
Total ratings
57.14%
Success rate
-0.6%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Overweight | $26 → $19 | $7.63 | +149.02% | 6 | May 2, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $58 → $59 | $62.11 | -5.01% | 7 | Apr 30, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $25 | $10.94 | +128.62% | 5 | Apr 9, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $80 → $91 | $64.39 | +41.33% | 5 | Apr 7, 2025 | |
| CABA Cabaletta Bio | Maintains: Equal-Weight | $6 → $3 | $1.28 | +134.38% | 10 | Apr 1, 2025 | |
| SEPN Septerna | Maintains: Equal-Weight | $14 → $11 | $7.19 | +52.99% | 3 | Mar 28, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Equal-Weight | $11 → $10 | $4.63 | +115.98% | 5 | Mar 21, 2025 | |
| QTTB Q32 Bio | Maintains: Equal-Weight | $16 → $15 | $1.56 | +861.54% | 2 | Mar 12, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $723 → $741 | $656.65 | +12.85% | 11 | Feb 28, 2025 | |
| EXEL Exelixis | Downgrades: Equal-Weight | $36 | $39.84 | -9.64% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $51 | $20.77 | +145.55% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $6 | $1.36 | +341.18% | 4 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $12.85 | +8.95% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $4.30 | +109.30% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $15.23 | +195.47% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $12 | $1.62 | +640.74% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $27 | $13.13 | +105.64% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $13 | $2.55 | +410.81% | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $38 → $57 | $33.63 | +69.49% | 7 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $2.13 | +1,026.76% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $43 → $30 | $19.98 | +50.15% | 10 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $151 | $101.86 | +48.24% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $3.58 | +375.52% | 1 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $264 → $289 | $170.74 | +69.26% | 13 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $1.39 | +694.22% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $20.29 | +82.36% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $1.82 | +450.96% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $1.05 | +1,804.76% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.57 | +404.91% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.53 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $27.14 | +611.13% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $80.14 | -48.84% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $10.67 | +1,399.53% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $9.25 | +548.65% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.60 | +530.43% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $2.13 | +2,247.42% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $10.95 | +365.75% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $25.25 | +248.58% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $25.72 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $16.39 | - | 2 | Aug 3, 2017 |
Arvinas
May 2, 2025
Maintains: Overweight
Price Target: $26 → $19
Current: $7.63
Upside: +149.02%
Incyte
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $58 → $59
Current: $62.11
Upside: -5.01%
Nurix Therapeutics
Apr 9, 2025
Maintains: Overweight
Price Target: $32 → $25
Current: $10.94
Upside: +128.62%
Rhythm Pharmaceuticals
Apr 7, 2025
Maintains: Overweight
Price Target: $80 → $91
Current: $64.39
Upside: +41.33%
Cabaletta Bio
Apr 1, 2025
Maintains: Equal-Weight
Price Target: $6 → $3
Current: $1.28
Upside: +134.38%
Septerna
Mar 28, 2025
Maintains: Equal-Weight
Price Target: $14 → $11
Current: $7.19
Upside: +52.99%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $4.63
Upside: +115.98%
Q32 Bio
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $1.56
Upside: +861.54%
argenx SE
Feb 28, 2025
Maintains: Overweight
Price Target: $723 → $741
Current: $656.65
Upside: +12.85%
Exelixis
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $39.84
Upside: -9.64%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $20.77
Upside: +145.55%
Jan 30, 2025
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $1.36
Upside: +341.18%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $12.85
Upside: +8.95%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $4.30
Upside: +109.30%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $15.23
Upside: +195.47%
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $1.62
Upside: +640.74%
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $27
Current: $13.13
Upside: +105.64%
Dec 11, 2024
Maintains: Overweight
Price Target: $15 → $13
Current: $2.55
Upside: +410.81%
Dec 2, 2024
Upgrades: Overweight
Price Target: $38 → $57
Current: $33.63
Upside: +69.49%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $2.13
Upside: +1,026.76%
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $43 → $30
Current: $19.98
Upside: +50.15%
Oct 31, 2024
Maintains: Overweight
Price Target: $153 → $151
Current: $101.86
Upside: +48.24%
Oct 4, 2024
Initiates: Overweight
Price Target: $17
Current: $3.58
Upside: +375.52%
Sep 17, 2024
Maintains: Overweight
Price Target: $264 → $289
Current: $170.74
Upside: +69.26%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $1.39
Upside: +694.22%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $20.29
Upside: +82.36%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $1.82
Upside: +450.96%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $1.05
Upside: +1,804.76%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $3.57
Upside: +404.91%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $4.53
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $27.14
Upside: +611.13%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $80.14
Upside: -48.84%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $10.67
Upside: +1,399.53%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $9.25
Upside: +548.65%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.60
Upside: +530.43%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $2.13
Upside: +2,247.42%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $10.95
Upside: +365.75%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $25.25
Upside: +248.58%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $25.72
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $16.39
Upside: -